A detailed history of Wasatch Advisors Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Wasatch Advisors Inc holds 2,535,802 shares of MGNX stock, worth $8.22 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,535,802
Previous 2,451,797 3.43%
Holding current value
$8.22 Million
Previous $10.4 Million 19.94%
% of portfolio
0.04%
Previous 0.06%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.0 - $5.55 $252,015 - $466,227
84,005 Added 3.43%
2,535,802 $8.34 Million
Q2 2024

Aug 14, 2024

BUY
$3.31 - $18.51 $4.84 Million - $27.1 Million
1,462,218 Added 147.76%
2,451,797 $10.4 Million
Q1 2024

Apr 18, 2024

SELL
$9.77 - $21.47 $3.01 Million - $6.61 Million
-307,995 Reduced 23.74%
989,579 $14.6 Million
Q4 2023

Feb 14, 2024

SELL
$4.48 - $10.11 $501,580 - $1.13 Million
-111,960 Reduced 7.94%
1,297,574 $12.5 Million
Q3 2023

Nov 14, 2023

BUY
$4.48 - $6.19 $2,168 - $2,995
484 Added 0.03%
1,409,534 $6.57 Million
Q2 2023

Aug 07, 2023

BUY
$4.62 - $7.54 $405,774 - $662,238
87,830 Added 6.65%
1,409,050 $7.54 Million
Q1 2023

May 12, 2023

SELL
$4.82 - $7.24 $4.44 Million - $6.67 Million
-921,142 Reduced 41.08%
1,321,220 $9.47 Million
Q4 2022

Feb 14, 2023

SELL
$3.34 - $6.98 $2.2 Million - $4.59 Million
-657,687 Reduced 22.68%
2,242,362 $15 Million
Q3 2022

Nov 14, 2022

SELL
$3.01 - $5.22 $4.48 Million - $7.78 Million
-1,490,015 Reduced 33.94%
2,900,049 $10 Million
Q2 2022

Aug 12, 2022

BUY
$2.25 - $9.99 $784,631 - $3.48 Million
348,725 Added 8.63%
4,390,064 $13 Million
Q1 2022

May 13, 2022

SELL
$8.12 - $16.9 $546,979 - $1.14 Million
-67,362 Reduced 1.64%
4,041,339 $35.6 Million
Q4 2021

Feb 15, 2022

SELL
$15.91 - $21.88 $3.35 Million - $4.6 Million
-210,350 Reduced 4.87%
4,108,701 $65.9 Million
Q3 2021

Nov 12, 2021

BUY
$19.74 - $28.7 $3.98 Million - $5.78 Million
201,534 Added 4.89%
4,319,051 $90.4 Million
Q2 2021

Aug 12, 2021

BUY
$20.49 - $35.63 $299,194 - $520,269
14,602 Added 0.36%
4,117,517 $111 Million
Q1 2021

May 10, 2021

BUY
$18.99 - $33.2 $8.18 Million - $14.3 Million
430,499 Added 11.72%
4,102,915 $131 Million
Q4 2020

Feb 12, 2021

BUY
$19.41 - $26.0 $24 Million - $32.2 Million
1,238,692 Added 50.9%
3,672,416 $84 Million
Q3 2020

Nov 10, 2020

BUY
$24.69 - $31.6 $3.02 Million - $3.86 Million
122,142 Added 5.28%
2,433,724 $61.3 Million
Q2 2020

Aug 12, 2020

SELL
$5.2 - $29.12 $1.57 Million - $8.78 Million
-301,453 Reduced 11.54%
2,311,582 $64.5 Million
Q1 2020

May 08, 2020

BUY
$4.28 - $12.11 $1.78 Million - $5.03 Million
415,334 Added 18.9%
2,613,035 $15.2 Million
Q4 2019

Feb 13, 2020

BUY
$7.95 - $12.27 $6.3 Million - $9.73 Million
792,831 Added 56.43%
2,197,701 $23.9 Million
Q3 2019

Nov 14, 2019

SELL
$12.44 - $17.48 $216,145 - $303,715
-17,375 Reduced 1.22%
1,404,870 $17.9 Million
Q2 2019

Aug 07, 2019

BUY
$14.51 - $19.71 $1.9 Million - $2.58 Million
130,732 Added 10.12%
1,422,245 $0
Q1 2019

May 08, 2019

BUY
$11.11 - $25.6 $2.74 Million - $6.31 Million
246,536 Added 23.59%
1,291,513 $0
Q4 2018

Feb 14, 2019

SELL
$11.75 - $21.42 $16,685 - $30,416
-1,420 Reduced 0.14%
1,044,977 $13.3 Million
Q3 2018

Nov 07, 2018

BUY
$19.26 - $23.46 $679,820 - $828,067
35,297 Added 3.49%
1,046,397 $0
Q2 2018

Aug 02, 2018

SELL
$19.78 - $24.67 $77,854 - $97,101
-3,936 Reduced 0.39%
1,011,100 $0
Q1 2018

May 02, 2018

SELL
$18.89 - $32.46 $253,258 - $435,191
-13,407 Reduced 1.3%
1,015,036 $0
Q4 2017

Jan 16, 2018

SELL
$16.19 - $20.3 $255,607 - $320,496
-15,788 Reduced 1.51%
1,028,443 $0
Q3 2017

Nov 08, 2017

SELL
$15.52 - $18.94 $186 - $227
-12 Reduced -0.0%
1,044,231 $0
Q2 2017

Aug 16, 2017

BUY
N/A
1,044,243
1,044,243 $0

Others Institutions Holding MGNX

About MACROGENICS INC


  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $199M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Wasatch Advisors Inc Portfolio

Follow Wasatch Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wasatch Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wasatch Advisors Inc with notifications on news.